NISSUI PHARMACEUTICAL CO., LTD. Note:This document is a translation of a part of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.
Consolidated Financial Results
for the Six Months Ended September 30, 2021
[Japanese GAAP]
Company name: Nissui Pharmaceutical Co.,Ltd. | October 28, 2021 |
Stock exchange listing: Tokyo | |
Code number: 4550 | |
URL: https://www.nissui-pharm.co.jp | |
Representative: Tokuya Ono | President |
Contact: Shin Saitou | Board Member, Executive Officer |
Phone: 03-5846-5611
Scheduled date of filing quarterly securities report: November 05, 2021
Scheduled date of commencing dividend payments: December 06, 2021
Availability of supplementary briefing material on quarterly financial results: Yes
Schedule of quarterly financial results briefing session: No
(Amounts of less than one million yen are rounded down)
1. Consolidated Financial Results for the Six Months Ended September 30, 2021 (April 01, 2021 to September 30, 2021)
(1) Consolidated Operating Results | (% indicates changes from the previous corresponding period.) | |||||||||
Net sales | Operating profit | Ordinary profit | Profit attributable to | |||||||
owners of parent | ||||||||||
Six months ended | Million yen | % | Million yen | % | Million yen | % | Million yen | % | ||
September 30, 2021 | 8,366 | 68.9 | 857 | 183.1 | 928 | 132.3 | 655 | 150.3 | ||
September 30, 2020 | 4,953 | - | 302 | - | 399 | - | 261 | - |
(Note) Comprehensive income: | Six months ended September 30, 2021: |
Six months ended September 30, 2020: |
¥ | 719 million | [ | 110.2%] |
¥ | 342 million | [ | -%] |
Basic earnings | Diluted earnings per | ||
per share | share | ||
Six months ended | Yen | Yen | |
September 30, 2021 | 29.28 | - | |
September 30, 2020 | 11.70 | - |
(Note) We have adopted the "Accounting Standard for Revenue Recognition" (ASBJ Statement No.29, March 31,2020), etc., from the first quarter of the current consolidated fiscal year. Accordingly, all figures have been retroactively adopted to the above accounting standards; thus, we do not describe the difference in percentage between the previous fiscal year and the year before.
(2) Consolidated Financial Position
Total assets | Net assets | Capital adequacy ratio | |
As of | Million yen | Million yen | % |
September 30, 2021 | 36,716 | 32,744 | 89.2 |
March 31, 2021 | 35,801 | 32,472 | 90.7 |
(Reference) Equity: As of | September 30, 2021: | ¥ | 32,744 million |
As of | March 31, 2021: | ¥ | 32,472 million |
(Note) We have adopted the "Accounting Standard for Revenue Recognition" (ASBJ Statement No.29, March 31,2020), etc., from the first quarter of the current consolidated fiscal year. Accordingly, the figures of the fiscal year ended March 31, 2021, have been retroactively adopted to the above accounting standards.
1
2. Dividends
Annual dividends | ||||||||
1st | 2nd | 3rd | Year-end | Total | ||||
quarter-end | quarter-end | quarter-end | ||||||
Yen | Yen | Yen | Yen | Yen | ||||
Fiscal year ended March 31, 2021 | - | 10.00 | - | 20.00 | 30.00 | |||
Fiscal year ending March 31, 2022 | - | 25.00 | ||||||
Fiscal year ending March 31, 2022 | - | 15.00 | 40.00 | |||||
(Forecast) | ||||||||
(Note) Revision to the forecast for dividends | announced most | recently: | Yes | |||||
(Note) Breakdown of the 2nd quarter dividend for the fiscal year ending March 31, 2022 : | ||||||||
Commemorative dividend | 15 | yen | ||||||
Special dividend | 10 | yen |
3. Consolidated Financial Results Forecast for the Fiscal Year Ending March 31, 2022(April 01, 2021 to March 31, 2022)
(% indicates changes from the previous corresponding period.)
Net sales | Operating profit | Ordinary profit | Profit attributable to | Basic earnings | ||||||||
owners of parent | per share | |||||||||||
Million yen | % | Million yen | % | Million yen | % | Million yen | % | Yen | ||||
Full year | 14,350 | 19.9 | 1,270 | 57.8 | 1,410 | 47.4 | 980 | 49.3 | 43.76 | |||
(Note) Revision to the financial results forecast announced most recently: | Yes | |||||||||||
* Notes: | ||||||||||||
(1) Changes in significant subsidiaries during the six months ended September 30, 2021 | ||||||||||||
(changes in specified subsidiaries resulting in changes in scope of consolidation): | No | |||||||||||
New | - | (Company name: | ) | |||||||||
Exclusion: | - | (Company name: | ) | |||||||||
(2) Accounting policies adopted specially for the preparation of quarterly consolidated financial statements: | No |
- Changes in accounting policies, changes in accounting estimates and retrospective restatement
- Changes in accounting policies due to the revision of accounting standards: Yes
- Changes in accounting policies other than 1) above: No
- Changes in accounting estimates: No
- Retrospective restatement: No
- Total number of issued shares (common shares)
- Total number of issued shares at the end of the period (including treasury shares):
September 30, 2021: | 22,547,140 | shares |
March 31, 2021: | 22,547,140 | shares |
2) Total number of treasury shares at the end of the period: | ||
September 30, 2021: | 152,884 | shares |
March 31, 2021: | 152,799 | shares |
3) Average number of shares during the period: | ||
Six months ended September 30, 2021: | 22,394,300 | shares |
Six months ended September 30, 2020: | 22,394,420 | shares |
2
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Nissui Pharmaceutical Co. Ltd. published this content on 28 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 November 2021 01:51:04 UTC.
